Рациональный подход к терапии EGFR-позитивного рака легкого

СтатьяМЕД СОВЕТ. 2019; № 19: 51–56. DOI:10.21518/2079-701X-2019-19-51-56

Реутова Е.В.^[1]

Лактионов К.К.^[1]

Юдин Д.И.^[1]

Ардзинба М.С.^[1]

^[1]НИИ клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина

немелкоклеточный рак легкого

приобретенная резистентность

мутации EGFR

ингибиторы тирозинкиназы EGFR

T790M

Del19

L858R

Афатиниб

Больные

Здравоохранение

Карповые

Кинез

Москва

Мутация

Новообразований метастазы

Российская Федерация

Tjulandin S., Imyanitov E., Moiseyenko V., Ponomarenko D., Gurina L., Koroleva I., Karaseva V. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. Curr Med Res Opin. 2015;31(6):1117-27. doi: 10.1185/03007995.2015.1036015..
DOI: 10.1185/03007995.2015.1036015

Лактионов К. К., Артамонова Е. В., Бредер В. В., Горбунова В. А., Моисеенко Ф. В., Реутова Е. В. и соавт. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018;8(3s2):30–46. doi: 10.18027/2224–5057–2018–8–3s2–30–46..
DOI: 10.18027/2224–5057–2018–8–3s2–30–46

Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006;107(6):1207-1218. doi: 10.1002/cncr.22133..
DOI: 10.1002/cncr.22133

Lee C.K., Davies L., Wu Y.L., Mitsudomi T. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017;109(6). doi: 10.1093/jnci/djw279..
DOI: 10.1093/jnci/djw279

Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011;18(3):126-138. doi: 10.3747/co.v18i3.877..
DOI: 10.3747/co.v18i3.877

Yang J.C., Wu Y.L., Schuler M., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUXLung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–151. doi: 10.1016/S1470-2045(14)71173-8..
DOI: 10.1016/S1470-2045(14)71173-8

Urata Y., Katakami N., Morita S, et al. Randomized phase III study compar.ing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016;34(27):3248–3257. doi: 10.1200/JCO.2015.63.4154..
DOI: 10.1200/JCO.2015.63.4154

Yang J.J., Zhou Q., Yan H.H., et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017;116(5):568–574. doi: 10.1038/bjc.2016.456..
DOI: 10.1038/bjc.2016.456

Paz-Ares L., Tan E.H., O’Byrne K., et al. Afatinib versus gefitinib in patients with EGFR mutationpositive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270–277. doi: 10.1093/annonc/mdw611..
DOI: 10.1093/annonc/mdw611

Park K., Tan E.H., O’Byrne K., et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, openlabel, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589. doi: 10.1016/S1470-2045(16)30033-X..
DOI: 10.1016/S1470-2045(16)30033-X

Wu Y.L., Cheng Y., Zhou X., et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive nonsmall-cell lung cancer (ARCHER 1050): a randomised,open-label, phase 3 trial. Lancet Oncol 2017;18(11):1454–1466. doi: 10.1016/S1470-2045(17)30608-3..
DOI: 10.1016/S1470-2045(17)30608-3

Mok T.S., Cheng Y., Zhou X. et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994..
DOI: 10.1200/JCO.2018.78.7994

Arcila M.E., Oxnard G.R., Nafa K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17(5):1169-1180. doi: 10.1158/1078-0432.CCR-10-2277..
DOI: 10.1158/1078-0432.CCR-10-2277

Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. doi: 0.1371/journal.pmed.0020073..
DOI: 0.1371/journal.pmed.0020073

Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.19. doi: 10.1126/scitranslmed.3002003..
DOI: 10.1126/scitranslmed.3002003

Yang J.C., Ahn M.J., Kim D.W., et al. Osimertinib in pretreated T790M-positive advanced non-smallcell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–1296. doi: 10.1200/JCO.2016.70.3223..
DOI: 10.1200/JCO.2016.70.3223

Jenkins S., Chih-Hsin Yang J., Jänne P.A. et al. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Journal of Thoracic Oncology. 2017;12(8):1247-1256. doi: 10.1016/j.jtho.2017.05.002..
DOI: 10.1016/j.jtho.2017.05.002

Janne P.A., Yang J.C., Kim D.W., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi: 10.1056/NEJMoa1411817..
DOI: 10.1056/NEJMoa1411817

Mok T.S., Wu Y.L., Ahn M.J., et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi: 10.1056/NEJMoa1612674..
DOI: 10.1056/NEJMoa1612674

Huang W.L., Chen Y.L., Yang S.C. et al. Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget. 2017;8(11):18590-18608. doi: 10.18632/oncotarget.14613..
DOI: 10.18632/oncotarget.14613

Oxnard G.R., Thress K.S., Alden R.S. et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375-3382. doi: 10.1200/JCO.2016.66.7162..
DOI: 10.1200/JCO.2016.66.7162

Ahn M., Han J., Tsai C. et al. Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays. Presented at: IASLC 18th World Conference on Lung Cancer (WCLC). Yokohama, Japan, October 15–18, 2017. Available at: https://wclc2019.iaslc.org › WCLC2019-Abstract-Book_web-friendly.https://wclc2019.iaslc.org

Yu H.A., Arcila M.E., Rekhtman N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-2247. doi: 10.1158/1078-0432.CCR-12-2246..
DOI: 10.1158/1078-0432.CCR-12-2246

Soria J.C., Ohe Y., Vansteenkiste J., et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. doi: 10.1056/NEJMoa1713137..
DOI: 10.1056/NEJMoa1713137

Thress K.S., Paweletz C.P., Felip E., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–562. doi: 10.1038/nm.3854.
DOI: 10.1038/nm.3854

Niederst M.J., Hu H., Mulvey H.E. et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560..
DOI: 10.1158/1078-0432.CCR-15-0560

Wang Z., Yang J.J., Huang J. et al. Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. 2017;12(11):1723-1727. doi: 10.1016/j.jtho.2017.06.017..
DOI: 10.1016/j.jtho.2017.06.017

Ortiz-Cuaran S, Scheffler M, Plenker D et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837-4847. doi: 10.1158/1078-0432.CCR-15-1915..
DOI: 10.1158/1078-0432.CCR-15-1915

Santarpia M., Liguori A., Karachaliou N. et al. Osimertinib in the treatment of non-smallcell lung cancer: design, development and place in therapy. Lung Cancer (Auckl). 2017;8:109–125. doi: Santarpia M., Liguori A., Karachaliou N. et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl). 2017;8:109–125. doi: 10.2147/LCTT.S119644..
DOI: 10.2147/LCTT.S119644

Hochmair M.J., Morabito A., Hao D. et al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019;15(25):2905-2914. doi: 10.2217/fon-2018-0711..
DOI: 10.2217/fon-2018-0711

Hendriks L.E., Smit E.F., Vosse B.A. et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer. 2014;84(1):86–91. doi: 10.1016/j.lungcan.2014.01.006..
DOI: 10.1016/j.lungcan.2014.01.006

Iuchi T., Shingyoji M., Sakaida T., Hatano K., Nagano O., Itakura M., et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282-287. doi: 10.1016/j.lungcan.2013.08.016..
DOI: 10.1016/j.lungcan.2013.08.016

Park S.J., Kim H.T., Lee D.H. et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556–560. doi: 10.1016/j.lungcan.2012.05.092.
DOI: 10.1016/j.lungcan.2012.05.092

Yang J.C.H., Wu Y.-L., Hirsh V. et al. 143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7. Journal of Thoracic Oncology. 2018;13(4):S84-S85. doi: 10.1016/S1556-0864(18)30417-9..
DOI: 10.1016/S1556-0864(18)30417-9

Язык текста: Русский

ISSN: 2079-701X